This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.
RAPT Reports Positive Data From Atopic Dermatitis Study
by Zacks Equity Research
RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
by Zacks Equity Research
Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate
by Zacks Equity Research
Vertex (VRTX) to discontinue further development of AATD candidate, VX-864, as it appears unlikely to benefit patients.
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
by Zacks Equity Research
Omeros (OMER) announces initial results from a phase I study of OMS906.
Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children
by Zacks Equity Research
The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status
by Zacks Equity Research
VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
by Zacks Equity Research
Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids
by Zacks Equity Research
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold
by Zacks Equity Research
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
Repligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma.
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.
J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection
by Zacks Equity Research
The U.S. Supreme Court rejects J&J's (JNJ) appeal against a lower court verdict of $2.1 billion in damages in a litigation related to its talc-based baby powder.
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients
by Zacks Equity Research
Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
by Zacks Equity Research
Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study
by Zacks Equity Research
Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
Bristol Myers' (BMY) Opdivo-Yervoy Combo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo in combination with Yervoy gets positive CHMP recommendation by the EMA for an additional indication.
Regeneron (REGN)-Sanofi's Libtayo Gets Positive CHMP Opinion
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.
Bristol Myers (BMY) Gets FDA Nod for Another Opdivo Indication
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Opdivo (injection for intravenous use) for adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer.